companydata.dkcompanydata.dk

PULMOPHARMA ApS: Financial statements 2025

CVR: 36428023

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

PULMOPHARMA ApS (CVR 36428023) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934. The solvency ratio was 84.2%.

Gross Profit
DKK -49,353
Profit/Loss
DKK -49,353
Equity
DKK 11,436,934
Total Assets
DKK 13,581,786
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--49 t.-49 t.11.4 mio.0
2024--20 t.-20 t.7.4 mio.0
2023--47 t.-47 t.7.4 mio.0
2022--56 t.-63 t.3.4 mio.0
2021--80 t.-93 t.3.5 mio.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is PULMOPHARMA ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

PULMOPHARMA ApS: The 2024 annual report is outJun 18, 2025

PULMOPHARMA ApS has published its annual report for 2024. Gross profit came to DKK -20,499, and the net result was DKK -20,499.

LARS NYENSTAD ApS registered as owner of PULMOPHARMA ApSMar 27, 2025

As of March 27, 2025, LARS NYENSTAD ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 20%.

BENDIX-HOLDING ApS registered as owner of PULMOPHARMA ApSMar 27, 2025

As of March 27, 2025, BENDIX-HOLDING ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 20%.

LouMar ApS registered as owner of PULMOPHARMA ApSMar 27, 2025

As of March 27, 2025, LouMar ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 20%.

About PULMOPHARMA ApS

PULMOPHARMA ApS is a Danish company of the type Anpartsselskab based in Ebeltoft, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named PULMOPHARMA IVS. The management consists of Dan Mønster Nielsen. The board consists of Torben Ballegaard Sørensen (chair), Dan Mønster Nielsen, Per Bendix Jeppesen and Peter Frithjof Bang. The company's owners include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934.

Source: annual report 2025, Danish Business Authority